Fred Ehrsam, best known as a co-founder of Coinbase, is taking a much deeper step into neuroscience. His startup Nudge, launched in 2024, has introduced its first product: Nudge Zero, a non-invasive ultrasound neuromodulation device designed to interact with brain activity without surgery or permanent tissue alteration.
The launch marks a notable shift in focus for one of crypto’s most recognizable early builders. While Ehrsam remains associated with the digital asset industry through his role at Paradigm, the unveiling of Nudge Zero suggests that neuroscience has become a central frontier in his current work.
From Crypto Infrastructure to Brain Technology
Ehrsam and Brian Armstrong started Coinbase in a two-bedroom apartment more than a decade ago, helping build what would become one of the most influential companies in the cryptocurrency industry. Since then, both founders have accumulated significant wealth, and Ehrsam has increasingly directed his attention toward frontier technologies beyond crypto.
Before founding Nudge, Ehrsam co-founded Paradigm in 2018 with Sequoia veteran Matt Huang. The crypto-focused investment firm manages three funds, and its most recent vehicle closed at $850 million in June of last year. According to the source material, Ehrsam stepped down from his role as managing partner at Paradigm in 2023, though he remains involved as a general partner.
That background matters because it frames Nudge not as a side project, but as a serious long-term effort backed by an entrepreneur with experience building major technology companies and funding ambitious research-driven ventures. The report also notes that Ehrsam, now 36 years old, has an estimated net worth of $2.1 billion, giving him the flexibility to pursue capital-intensive scientific innovation.
What Nudge Zero Is Designed to Do
Nudge Zero is described as a non-invasive ultrasound neuromodulation device. In simple terms, that means it uses ultrasound waves to influence brain activity. Rather than requiring implants or surgery, the technology aims to affect cell membranes in the brain externally, without causing permanent change or damage.
Neuromodulation has attracted growing interest because it sits at the intersection of medicine, mental health, and human enhancement. In the article, the use cases for ultrasound-based neuromodulation are broadly divided into two categories. The first is medical, including neurological conditions such as epilepsy and pain management. The second is therapeutic, covering less acute but still meaningful issues such as depression and other forms of mental wellness support.
Nudge appears to be positioning its first product carefully within that spectrum. Ehrsam said the company plans to begin by targeting acute medical conditions in the coming months. That choice places the initial emphasis on more urgent, clinically oriented applications rather than immediately pursuing lifestyle or wellness branding.
A Longer-Term Consumer Vision
Although the first phase is focused on acute medical use, the company’s ambitions extend beyond narrowly defined clinical scenarios. Ehrsam said the eventual goal is to create a miniaturized version of the device, something closer in form to a pair of headphones, that could be used by healthy individuals to improve mood, cognition, and daily life.
That longer-term vision is significant because it points toward a broader thesis about brain-interface technology. Nudge is not merely presenting a one-off medical device; it is suggesting a path from specialized medical intervention to accessible, everyday neurotechnology. If realized, that would place the company in a category that spans healthcare, consumer hardware, and cognitive performance tools.
Nudge’s mission statement reflects that expansive ambition. According to the report, the startup aims to “develop the best technology for interfacing with the brain to improve people’s lives.” In Ehrsam’s own framing, technology should be directed toward improving the human experience, and building tools that interface with the brain is, in his view, one of the most direct ways to do that.
Why the Launch Matters Beyond Crypto
For crypto observers, the unveiling of Nudge Zero is notable not because it directly affects digital asset markets, but because it illustrates how some of the industry’s earliest entrepreneurs are redeploying capital and experience into adjacent frontier sectors. Ehrsam’s trajectory now spans three distinct arenas: exchange infrastructure through Coinbase, crypto investing through Paradigm, and brain technology through Nudge.
That progression also says something about the broader evolution of tech entrepreneurship. Founders who benefited from earlier waves of internet, fintech, or crypto innovation are increasingly moving toward fields such as biotech, neurotechnology, and advanced hardware. These sectors often require longer timelines, deeper research, and greater tolerance for uncertainty than software startups, but they also offer the possibility of much larger societal impact.
In that sense, Nudge Zero represents more than a product launch. It signals a transfer of attention from financial systems to biological systems, from digital coordination to human cognition. Whether the company succeeds clinically or commercially remains to be seen, but the strategic direction is already clear.
An Early Step in a Much Larger Bet
Based on the source material, Nudge Zero is still at the beginning of its journey. The device will first be used in attempts to treat acute conditions, and any future path toward consumer adoption depends on technical validation, regulatory progress, and continued product development. The article does not claim that these future milestones have been achieved, only that they are part of the company’s stated ambition.
Still, the launch gives the market a concrete first look at what Ehrsam has been building since founding Nudge in 2024. For a figure long associated with crypto, the message is unmistakable: his next frontier is the brain.
If Coinbase helped define one chapter of Ehrsam’s career and Paradigm another, Nudge may become the vehicle for a third—one centered not on blockchains or capital markets, but on the challenge of developing practical technologies to interact with the human mind.